Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REC 603

X
Drug Profile

REC 603

Alternative Names: REC-603; Recombinant HPV 9-valent vaccine - Jiangsu Recbio Technology

Latest Information Update: 12 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Recbio Technology
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cervical cancer; Condylomata acuminata

Most Recent Events

  • 09 Aug 2022 Jiangsu Recbio Technology completes enrolment in its phase-III trial for Cervical cancer and genital warts (Prevention) in China
  • 21 Mar 2022 Jiangsu Recbio Technology plans to launch REC 603, on approval, in China
  • 20 Mar 2022 Jiangsu Recbio Technology plans to submit BLA to NMPA in 2025
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top